On March 7, 2024, the Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib, marketed as Brukinsa by BeiGene…
Browsing: zanubrutinib
In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology, investigates a combination therapy for…
Zanubrutinib Outperforms Ibrutinib in Treating Relapsed/Refractory CLL/SLL Mehrdad Mobasher MD By Mehrdad Mobasher, MD, MPH The ALPINE study was a…
Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia By Elizabeth Brém, MD from UCI Health We focused basically on two…
Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia So I’m gonna start with chronic lymphocytic leukemia. And as part of…
Zanubrutinib: Superior PFS in CLL Jennifer Brown, MD – ASH 2022 By Jennifer Brown, MD I’ll be discussing the alpine…